Revenue segments as reported by the company.

Product sales

Royalty, contract and other revenues

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Acquired in-process research and development expenses

Selling, general and administrative

In-process research and development impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Gilead Sciences reports robust earnings, eyes pipeline opportunities for growth

Gilead Sciences delivered strong financial performance in Q4 2022, driven by growth in key product sales. Despite facing challenges in the HIV market for Q1 2023, the company remains focused on leveraging opportunities in its pipeline and strategic investments.

Gilead reports strong Q1 sales, focuses on pipeline growth

Gilead Sciences delivered strong sales driven by key products in Q1 2023.
While facing challenges like lower Veklury sales, Gilead maintains revenue guidance.
The company's strengths lie in its pipeline, successful products, and manufacturing capabilities.
Opportunities in new indications and therapies position Gilead for future growth.

Gilead Sciences reports robust Q2 performance and eyes future growth

Gilead Sciences had a strong quarter with growth in sales and positive pipeline updates.
Trodelvy's performance in different markets and potential Medicare coverage are key highlights.
Challenges include unsuccessful trials and addressing revenue aspirations.
Opportunities lie in expanding BD activities and exploring cell therapy beyond oncology.

Gilead Sciences reports robust Q3 performance amidst market challenges

Gilead Sciences demonstrated strong performance in Q3 2023, driven by growth in base business, oncology, and HIV segments.
While facing challenges such as declining Veklury sales and barriers to CART therapy uptake, Gilead is actively addressing opportunities for growth and market expansion.
The company's strengths lie in robust product sales, particularly in Biktarvy and Trodelvy, with a focus on innovation and strategic positioning in key therapeutic areas.
Overall, Gilead's performance reflects resilience and strategic planning amidst evolving market dynamics and competitive landscapes.

Gilead Sciences reports strong 2023 performance, eyes transformative therapies

Gilead Sciences showcased solid performance in 2023 with notable growth in key product sales areas, despite facing challenges in certain clinical trials. The company's strengths lie in its diverse portfolio, pipeline innovation, and commitment to delivering transformative therapies. With a focus on addressing HIV, oncology, and inflammation, Gilead is well-positioned for future growth and success.

Gilead Sciences reports robust Q1 performance and eyes future growth

Gilead Sciences delivered strong Q1 results driven by oncology and HIV product sales.
Challenges include IP R&D charge from Sema Bay acquisition and competitive market dynamics.
Opportunities lie in expanding cell therapy leadership, advancing HIV pipeline, and upcoming pipeline updates.
Overall, Gilead remains focused on growth through innovation and strategic portfolio advancements.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Galapagos

Galapagos NV/S ADR (NASDAQ: GLPG) shares were trading higher Monday after the company announced it has entered into a research and development collaboration with Gilead Sciences, Inc.

Galapagos Notches $3.95B Upfront Investment From Gilead

Gilead (GILD) collaborates with Galapagos for additional compounds for $5.1 billion and ups its stake in the latter to 22%.

Gilead-Galapagos Ink $5.1B Deal for Additional Compounds

U.S. antiviral drugmaker Gilead Sciences will invest $5.1 billion in a major expansion of its partnership with Belgo-Dutch biotech Galapagos NV.

Factbox: The Galapagos drugs pipeline that has drawn in Gilead

U.S. antiviral drugmaker Gilead Sciences  will invest $5.1 billion in a major expansion of its partnership with Belgo-Dutch biotech Galapagos NV , news that lifted Galapagos's shares 18 percent to an all-time high on Monday.

Gilead invests $5 bln to deepen ties with biotech Galapagos

Gilead Sciences Inc will invest $5.1 billion to raise its stake in Galapagos NV and partner with the Belgian-Dutch biotech firm to develop and commercialize its treatments for a ten-year period, the companies said on Sunday.

Gilead deepens Galapagos ties with $5.1 billion deal

Gilead Sciences Inc  will invest $5.1 billion to increase its stake in Galapagos NV  and partner with the Belgian-Dutch biotech firm to develop and commercialize its treatments for a ten-year period, the companies said on Sunday.

Pharma firm Gilead to raise Galapagos stake in $5.1 billion deal

Alexion Pharma

Amgen

Biogen

Celgene

MannKind

The short interest data are out for the most recent settlement date, June 28. Generally speaking, companies within the biotech industry are considered a riskier group of stocks, with big potential upside and big potential downside.

Short Sellers Run for Cover From Major Biotechs

Eli Lilly

Merck

Novo Nordisk

Sanofi

Teva Pharmaceutical

The recent ruling by a federal court against the Trump regime's decree to disclose the price labels of drugs in TV adverts resumes the spotlight on drug pricing.

Court Ruling Topples Trump Order, No Price Display in TV Ads

AbbVie

Allergan

Bristol-Myers

With key drugs losing exclusivity, key drug makers are poised to face deep trouble since their sales are mostly dependent on a single drug.

Will Patent Woes Boost Pharma Stock Megamergers Further?

Pfizer

Regeneron Pharmaceuticals

While the public wants more pharmaceuticals and biotech advancements to treat the endless number of ailments or to extend their lives, there is a simultaneous push to make drugs more affordable.

Many Top Pharma & Biotechs Rise As Drug Price Disclosure Thrown Out

Gilead Sciences, Inc. (NASDAQ: GILD), which has recently faced a setback with its NASH pipeline and is grappling with an aging HIV franchise, is partnering with a privately held company to develop HIV therapies with the goal of improving medication adherence.

Gilead, Lyndra Therapeutics Partner On Ultra-Long-Acting HIV Drugs

Juniper Networks

The S&P is likely to slip early in the week and rally later in the week.

Buy Juniper Networks And Gilead Sciences

Johnson & Johnson

Rogers

Novartis

Learn how the marriage of science and technology is changing the world of medicine and creating some of the largest multinational biotechnology corporations.

The Top 10 Biotechnology Companies (JNJ, ROG.VX)

Vertex Pharmaceuticals

Large biotech companies Gilead Sciences and Vertex Pharmaceuticals are poised to beat Wall Street's second-quarter revenue expectations, according to investment bank RBC Capital Markets.

Why These 4 Biotech Leaders Could Rebound On Strong Earnings

Gilead stands a chance of competing with AbbVie in rheumatoid arthritis treatment, analysts said Tuesday. Late Monday, Gilead said it plans to ask the FDA to approve the drug by year-end.

Why This Gilead-AbbVie Rivalry Could Come To A Head In 2020

Gilead (GILD) is planning to submit regulatory application to the FDA seeking approval for filgotinib as a treatment for rheumatoid arthritis.

Gilead to Submit NDA for Inflammation Drug Filgotinib in '19

Regeneron (REGN) wins approval for skin cancer drug, Libtayo, in the European Union.

Regeneron/Sanofi's Libtayo Gets EU Approval for Skin Cancer

The big biotech waxes optimistic about a top drug in its pipeline.

After Hours: Gilead to Make Arthritis Drug Submission Soon

Gilead Sciences Inc. GILD, +0.40% announced Monday afternoon that it plans to ask the Food and Drug Administration to approve an arthritis drug this year.

Gilead plans to submit arthritis drug to FDA this year

AbbVie and Gilead shares have fallen considerably from their highs as serious concerns about future revenues have arisen.

AbbVie And Gilead - Two Different Strategies To Improve Growth

Recently launched Biktarvy has already attained the position of #1 prescribed regimen in U.S.

5 Reasons Why You Should Be Interested In Gilead Sciences

Gilead (GILD) teams up with Carna Biosciences to develop and commercialize small molecule compounds in immuno-oncology.

Gilead Inks Deal With Carna Biosciences for Immuno-Oncology

Gilead announced a partnership with Nurix to develop drugs against cancer and other diseases by using protein degradation.

Gilead's Latest Bolt-On Buys Point To A New Way Of Approaching Drug Development

Roche Holding AG

Here's how these biotech stocks became the biggest on the market -- and how their future prospects look.

The 10 Biggest Biotech Stocks

Gilead (GILD) collaborates with Nurix Therapeutics to leverage the proprietary drug discovery platform of the latter to identify novel agents that induce degradation of specified drug targets.

News for Gilead Sciences Stock (GILD)